Werewolf more than doubles on Ambros Therapeutics merger
HOWL•Funding and merger timeline
** Companies secure $150 million in new funding, which is expected to support operations and clinical trials into early 2029
** After the merger closes, expected in Q1 2027, combined company to operate as Ambros Therapeutics and trade on Nasdaq under ticker 'AMBX'
Shares jump on all-stock merger
** Shares of Werewolf Therapeutics HOWL.O rise 141% to $1.04 premarket
** Werewolf will merge with privately held Ambros Therapeutics in an all-stock deal
